NCT06334783

TIL for Patients With Advanced Solid Tumor

Terminated Phase 1 Last updated 21 January 2026

What this trial tests

Phase 1 trial testing Autologous tumor-infiltrating lymphocyte cells in Advanced Solid Tumor in 5 participants. Terminated before completion.

Timeline

30 May 2023

Primary endpoint
31 January 2025

31 July 2025

Quick facts

Lead sponsor	Hervor Therapeutics
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	5
Start date	30 May 2023
Primary completion	31 January 2025
Estimated completion	31 July 2025
Sites	3 locations across China

Drugs / interventions tested

• Autologous tumor-infiltrating lymphocyte cells — full drug profile →

Conditions studied

• Advanced Solid Tumor — all drugs for Advanced Solid Tumor →

Sponsor

Hervor Therapeutics — full company profile →

Who can join

Adults 18 to 75, any sex, with Advanced Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background:

Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy by harvesting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro and then infusing back to patients.

TIL therapy has shown strong efficacy for the treatment of solid tumors and has achieved high objective response rates in multiple cancers, such as melanoma, NSCLC, and cervical cancer.

Objective:

To evaluate the safety and efficacy of TIL for the patients with advanced solid tumor.

Eligibility:

Adults aging 18-75 with advanced solid tumor.

Design:

1. Patients will undergo screening tests, including imaging procedures, heart and lung tests, and lab tests.
2. Freshly resected patient tumors were dissected by the surgeon.
3. TIL cells were isolated from the patient's tumor tissue, then cultured in vitro, activated and expanded.
4. At last TIL cells will be re-infused into the patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Advances in Adoptive Cell Therapies in Cancer: From Mechanistic Breakthroughs to Clinical Frontiers and Overcoming Barriers.
   Rabbani SA, El-Tanani M, El-Tanani Y, Kumar R, et al · · 2025 · cited 1× · PMID 40981188 · DOI 10.3390/medsci13030190